Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma

D Prukova, L Andera, Z Nahacka, J Karolova… - Clinical Cancer …, 2019 - AACR
Purpose: Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodgkin
lymphomas characterized by (over) expression of BCL2. A BCL2-targeting drug, venetoclax …

[HTML][HTML] Current immunotherapy approaches in non-Hodgkin lymphomas

R Pytlik, K Polgarova, J Karolova, P Klener - Vaccines, 2020 - mdpi.com
Non-Hodgkin lymphomas (NHLs) are lymphoid malignancies of B-or T-cell origin. Despite
great advances in treatment options and significant improvement of survival parameters, a …

Combined treatment of primary vitreoretinal lymphomas significantly prolongs the time to first relapse

A Klimova, J Heissigerova, E Rihova… - British Journal of …, 2018 - bjo.bmj.com
Background Vitreoretinal lymphomas belong to the family of central nervous system (CNS)
lymphomas. The optimal approach for the treatment of isolated primary vitreoretinal …

[HTML][HTML] Combination treatment targeting mTOR and MAPK pathways has synergistic activity in multiple myeloma

K Sun, L Jin, J Karolová, J Vorwerk, S Hailfinger… - Cancers, 2023 - mdpi.com
Simple Summary Multiple myeloma (MM) is characterized by the clonal accumulation of
abnormal plasma cells in the bone marrow. Although current treatments have improved the …

Anti-apoptotic MCL1 protein represents critical survival molecule for most Burkitt lymphomas and BCL2-negative diffuse large B-cell lymphomas

M Klanova, D Kazantsev, E Pokorna, T Zikmund… - Molecular Cancer …, 2022 - AACR
The pro-survival MCL1 protein is overexpressed in many cancers, including B-cell non–
Hodgkin lymphomas (B-NHL). S63845 is a highly specific inhibitor of MCL1. We analyzed …

Sequencing‐based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy

J Karolová, D Kazantsev, M Svatoň… - American Journal of …, 2023 - Wiley Online Library
Our knowledge of genetic aberrations, that is, variants and copy number variations (CNVs),
associated with mantle cell lymphoma (MCL) relapse remains limited. A cohort of 25 patients …

[HTML][HTML] Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas

R Jakša, J Karolová, M Svatoň, D Kazantsev… - Laboratory …, 2022 - nature.com
Non-Hodgkin lymphomas (NHL) represent the most common hematologic malignancies.
Patient-derived xenografts (PDXs) are used for various aspects of translational research …

Preclinical evaluation of a novel SHIP1 phosphatase activator for inhibition of PI3K signaling in malignant B cells

EA Lemm, B Valle-Argos, LD Smith, J Richter… - Clinical Cancer …, 2020 - AACR
Purpose: PI3K signaling is a common feature of B-cell neoplasms, including chronic
lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL), and PI3K inhibitors …

[HTML][HTML] Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma

R Pola, E Pokorná, P Vočková, E Böhmová, M Pechar… - Acta Biomaterialia, 2021 - Elsevier
Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphoma (B-NHL)
with chronically relapsing clinical course. Implementation of cytarabine (araC) into induction …

Sequencing-Based Analysis of Clonal Evolution of 25 Mantle Cell Lymphoma Patients at Diagnosis and after Failure of Standard Immunochemotherapy

J Karolova, D Kazantsev, M Svaton, L Tušková… - Blood, 2022 - ashpublications.org
Mantle cell lymphoma (MCL) is a rare chronically relapsing subtype of aggressive B-cell non-
Hodgkin lymphoma characterized by the canonical chromosomal translocation t (11; 14) and …